Cargando…

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

INTRODUCTION: A new treatment plan was implemented at Skåne University Hospital, on economic grounds, for children requiring recombinant human growth hormone (rhGH) treatment. This involved switching patients from treatment with originator rhGHs to treatment with a biosimilar rhGH, somatropin (Omnit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flodmark, Carl-Erik, Lilja, Katarina, Woehling, Heike, Järvholm, Kajsa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873057/ https://www.ncbi.nlm.nih.gov/pubmed/24392303 http://dx.doi.org/10.1007/s13554-013-0011-z

Ejemplares similares

To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”
por: Ekelund, Mats, et al.
Publicado: (2014)

Depression, anxiety, and suicidal ideation in young adults 5 years after undergoing bariatric surgery as adolescents
por: Järvholm, Kajsa, et al.
Publicado: (2020)

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018)

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
por: Rashid, Nazia, et al.
Publicado: (2014)

Erratum to: Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
por: Rashid, Nazia, et al.
Publicado: (2014)

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study
por: Gerdes, S., et al.
Publicado: (2017)

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2018)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
por: Di Giuseppe, Daniela, et al.
Publicado: (2021)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
por: Liu, Yifei, et al.
Publicado: (2019)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
por: Petit, Juliette, et al.
Publicado: (2021)

The Law and Ethics of Switching from Biologic to Biosimilar in Canada
por: Murdoch, Blake, et al.
Publicado: (2020)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
por: Fischer, Sarah, et al.
Publicado: (2021)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2020)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
por: Kirsten, Natalia, et al.
Publicado: (2022)

The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars
por: Mazzoni, Davide, et al.
Publicado: (2021)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
por: Massimi, Davide, et al.
Publicado: (2021)

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study
por: Fisher, Anat, et al.
Publicado: (2022)

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial
por: Goll, G. L., et al.
Publicado: (2019)

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes
por: von Richter, Oliver, et al.
Publicado: (2016)

Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity: a prospective five-year Swedish nationwide study (AMOS)
por: Olbers, Torsten, et al.
Publicado: (2017)

Teamwork()
por: Ganança, Fernando F.
Publicado: (2014)

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar
por: Martínez-Feito, Ana, et al.
Publicado: (2020)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_403p025sumkdl8ck39tt7vpi35